Restylane Lyft Lidocaine 1x1ml
Important Notice
Medical device regulated by the European Medical Device Regulation (MDR), intended exclusively for authorized healthcare professionals. By purchasing, the customer declares to be authorized for their professional activity; false information may entail legal responsibilities.
Restylane Lyft with lidocaine is the firmest NASHA® gel in the Galderma range: G′ of 799 Pa with a deformability of 17 %. It is formulated to restore volume and projection in the mid third of the face and is the only product in the line with a documented indication for the dorsum of the hands, in addition to the correction of deep folds.
- Stabilised HA 20 mg/ml
- Lidocaine 3 mg/ml (0.3 %)
- Technology NASHA®
- Contents 1 syringe × 1.0 ml
- Needle 29G TW ½"
Composition and technology
- Stabilised hyaluronic acid: 20 mg/ml, of non-animal origin, cross-linked with BDDE and suspended in phosphate buffer solution at pH 7.
- Lidocaine hydrochloride: 3 mg/ml (0.3 %).
- NASHA® technology: large-particle particulate gel, the largest particle size in the NASHA family. The combination of minimal cross-linking and large particle size is what generates the lifting capacity.
- Rheological profile: G′ 799 Pa at 0.1 Hz, the highest firmness value in the entire Restylane range, with a deformability of 17 %. Maximum projection per millilitre; in return, it is not a gel for areas of intense facial expression.
Position within the range: NASHA and OBT
The entire Restylane range is built on two different gel technologies. Choosing between them is the first clinical decision of the treatment.
NASHA® (Non-Animal Stabilized Hyaluronic Acid): firm, particulate gels that retain the long hyaluronic acid chains with minimal cross-linking. High resistance and very low tolerance to deformation: projection, definition and structural support in areas that must hold their shape.
OBT™ (Optimal Balance Technology, called XpresHAn Technology™ in the US market): soft, flexible gels with a variable degree of cross-linking. Low to intermediate resistance and high tolerance to deformation: the gel follows the movement of the tissue, so it is intended for dynamic and expressive areas.
| NASHA — firmness and projection | G′ 416–799 Pa · deformability 7–19 % |
|---|---|
| Restylane / Classyc Lidocaine | HA 20 mg/ml · G′ 701 Pa · 7 % — wrinkles in the mid dermis, lips |
| Restylane Lyft Lidocaine | HA 20 mg/ml · G′ 799 Pa · 17 % — cheekbones, mid third of the face, dorsum of the hands |
| Restylane Eyelight | HA 20 mg/ml — infraorbital hollowing, supraperiosteal plane |
| Restylane Skinboosters Vital / Vital Light | HA 20 and 12 mg/ml — skin quality and hydration, without volumetric purpose |
| OBT / XpresHAn — flexibility and expression | G′ 70–271 Pa · deformability 761–1,442 % |
| Restylane Refyne | HA 20 mg/ml · G′ 70 Pa · 1,442 % — moderate wrinkles and folds |
| Restylane Kysse | HA 20 mg/ml · G′ 160 Pa · 908 % — lips, submucosal plane |
| Restylane Volyme | HA 20 mg/ml · G′ 171 Pa · 930 % — malar volume, supraperiosteal or subcutaneous |
| Restylane Defyne | HA 20 mg/ml · G′ 271 Pa · 761 % — severe wrinkles and folds |
The G′ (0.1 Hz) and deformability (xStrain) values come from peer-reviewed literature (J Drugs Dermatol 2024;23(12):1332–1338). Galderma does not publish official rheological values.
Indications and treatment areas
- Cheekbones and mid third of the face: malar augmentation and correction of the contour deficit of the mid third — subcutaneous to supraperiosteal plane.
- Moderate to severe facial folds and wrinkles (nasolabial fold) — deep dermis to superficial subcutaneous tissue.
- Dorsum of the hands: correction of the volume deficit — subcutaneous plane.
Maximum volumes per session according to the registration documentation: 6.0 ml in facial folds, 6.0 ml in malar augmentation and 3.0 ml per hand.
Technique and treatment protocol
- Injection plane: according to the area — deep dermis or superficial subcutis in folds; subcutaneous to supraperiosteal in the mid third of the face; subcutaneous on the dorsum of the hands.
- Needle: 29G thin wall (TW) ½", the one used in the registration studies.
- Technique: supraperiosteal bolus deposit or linear retrograde threading, according to the area. On the dorsum of the hand, pinch and lift the tissue before injecting in order to remain in the subcutaneous plane.
- Prior aspiration in accordance with standard clinical protocol. The mid third of the face is an area of significant vascular risk.
- Documented duration: according to Galderma's patient information, in nasolabial wrinkles 96 % of subjects showed an improvement at 12 weeks and 79 % at 48 weeks; in malar volume, around 90 % at 2 months and more than 50 % at one year. Efficacy and safety beyond one year have not been investigated in a clinical trial.
Technical data
| Manufacturer | Q-Med AB (Galderma) — Seminariegatan 21, SE-752 28 Uppsala, Sweden |
|---|---|
| Active substance | Stabilised hyaluronic acid 20 mg/ml, non-animal origin |
| Anaesthetic | Lidocaine hydrochloride 3 mg/ml (0.3 %) |
| Cross-linker | BDDE |
| Technology | NASHA® — large particle |
| Vehicle / pH | Phosphate buffer solution, pH 7 |
| Rheology | G′ 799 Pa · deformability 17 % |
| Presentation | 1 pre-filled syringe of 1.0 ml |
| Needle | 29G TW ½" |
| Application plane | Deep dermis, subcutaneous or supraperiosteal according to the area |
| Classification | CE-marked medical device (MDR 2017/745) |
| Use | Qualified healthcare professionals only |
Storage and pack contents
- Storage: up to 25 °C. Protect from freezing and from sunlight.
- Do not use after the expiry date shown on the pack.
- Single-use product. Do not reuse or re-sterilise.
- The pack contains: 1 pre-filled syringe of 1.0 ml, sterile needle(s) 29G TW ½", instructions for use and traceability labels for the patient record.
Contraindications and warnings
Contraindications (Galderma instructions for use): known hypersensitivity to streptococcal proteins or to any component of the product; history of severe allergies or of an anaphylactic reaction; hypersensitivity to lidocaine or to amide-type local anaesthetics; porphyria; active skin inflammation or infection in the area to be treated.
Precautions and individual assessment: coagulation disorders or anticoagulant or antiplatelet therapy (increased risk of haematoma and bleeding at the puncture site); history of hypertrophic or keloid scarring; autoimmune disease; presence of permanent implants in the area.
Warnings: do not inject intravascularly or intramuscularly. Intravascular injection can cause embolisation, vascular occlusion, ischaemia, skin necrosis, visual disturbance, blindness or stroke. Aspiration before injecting and low, constant injection pressure are recommended. Do not mix the gel with other products.
Always consult the instructions for use included in the pack before application.
Medical device intended exclusively for qualified healthcare professionals. Technical information based on the manufacturer's official documentation (Restylane® Lyft™ with lidocaine instructions for use and patient information, Q-Med AB / Galderma). This data sheet does not replace the instructions for use accompanying the product.